 |
67 Companies | 59 Products |
|
|
59 Products | |
344 Diseases | |
342 Trials |  |
12240 News |  |
| «12...6465666768697071727374...229230» |
- || Review, Journal, IO biomarker: An Insight on Novel Molecular Pathways in Metastatic Prostate Cancer: A Focus on DDR, MSI and AKT. (Pubmed Central) - Jan 12, 2022
Furthermore, the PTEN-PI3K-AKT pathway is another possible treatment target being investigated. In this review, we explore the current knowledge on these frequent genomic alterations of metastatic prostate cancer, their possible therapeutic repercussions and the promising future treatments under evaluation.
- ||| MYOD1 L122R mutated rhabdomyosarcomas are an area of urgent need. They commonly harbor additional alterations in the PI3K/AKT pathway but their targetability in this context wasn’t investigated before. (Twitter) - Jan 12, 2022
- | Journal: Polymorphisms in the mTOR-PI3K-Akt pathway, energy balance-related exposures and colorectal cancer risk in the Netherlands Cohort Study. (Pubmed Central) - Jan 12, 2022
Current data suggest that the mTOR-PI3K-Akt pathway may be involved in colon cancer development. This study thereby sheds more light on colon cancer etiology through use of genetic variation in the mTOR-PI3K-Akt pathway.
- || taselisib (GDC-0032) / Roche
Clinical, P1 data, Journal, Pan tumor: Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with PIK3CA-Mutant Cancers. (Pubmed Central) - Jan 11, 2022
Taselisib had limited activity in the tumor types tested and is no longer in development. This genome-driven study improves understanding of the activity, limitations, and resistance mechanisms of using PI3K inhibitors as monotherapy to target PIK3CA-mutant tumors.
- | Journal: Circ-PRMT5 promotes breast cancer by the miR-509-3p/TCF7L2 axis activating PI3K/AKT pathway. (Pubmed Central) - Jan 11, 2022
This genome-driven study improves understanding of the activity, limitations, and resistance mechanisms of using PI3K inhibitors as monotherapy to target PIK3CA-mutant tumors. Overall, our data indicate that the circ-PRMT5/miR-509-3p/TCF7L2 axis can aggravate the malignant character of breast cancer cells by the regulation of the PI3K/AKT pathway.
- | Journal, Cancer stem cells: PI3K-driven HER2 expression is a potential therapeutic target in colorectal cancer stem cells. (Pubmed Central) - Jan 11, 2022
While PI3K targeting kills liver-colonising CR-CSCs, the concomitant inhibition of PI3K, HER2 and MEK is required to induce regression of tumours resistant to anti-EGFR therapies. These data may provide a rationale for designing clinical trials in the adjuvant and metastatic setting.
- | Journal: MicroRNA-185 activates PI3K/AKT signaling pathway to alleviate dopaminergic neuron damage via targeting IGF1 in Parkinson's disease. (Pubmed Central) - Jan 11, 2022
These data may provide a rationale for designing clinical trials in the adjuvant and metastatic setting. This study illustrates that miR-185 ameliorates dopaminergic neuron damage via targeting IGF1 and activating PI3K/AKT signaling pathway in PD, which renews the therapy for PD.
- | LY294002 / Eli Lilly
Journal: PI3K/Akt Signaling Pathway Ameliorates Oxidative Stress-Induced Apoptosis upon Manganese Exposure in PC12 Cells. (Pubmed Central) - Jan 11, 2022
Meanwhile, LY294002 pretreatment also increased cell apoptosis given the upregulated Bax and Caspase-3 mRNAs and decreased Bcl-2 mRNA. In summary, the PI3K/Akt signaling pathway can be activated by MnSO exposure and mediate MnSO-induced neurotoxicity.
- | Journal: Germacrone improves liver fibrosis by regulating the PI3K/AKT/mTOR signalling pathway. (Pubmed Central) - Jan 11, 2022
Following GM treatment, the phosphorylation of the PI3K, AKT, and mTOR proteins was reduced in the liver of CCl -treated rats and TGF-?1-stimulated LX-2 cells, indicating that GM may attenuate hepatic fibrosis via the PI3K/AKT/mTOR signalling pathway. These outcomes highlight the anti-fibrotic effects of GM and suggest that it is a potential therapeutic agent for the treatment of liver fibrosis.
- | SB202190 / Amgen
Journal: Atractylodin inhibited the migration and induced autophagy in cholangiocarcinoma cells via PI3K/AKT/mTOR and p38MAPK signalling pathways. (Pubmed Central) - Jan 11, 2022
These outcomes highlight the anti-fibrotic effects of GM and suggest that it is a potential therapeutic agent for the treatment of liver fibrosis. ATD inhibits the proliferation and induces CCA cell autophagy via regulating PI3K/AKT/mTOR and p38MAPK signalling pathways.
- | doxorubicin hydrochloride / Generic mfg.
Journal: Silencing of the CrkL gene reverses the doxorubicin resistance of K562/ADR cells through regulating PI3K/Akt/MRP1 signaling. (Pubmed Central) - Jan 11, 2022
Together, we indicated that CrkL is up-regulated in myelogenous leukemia cells and silencing of CrkL could reverse Doxorubicin resistance effectively. These results show a potential novel strategy for intervention chemoresistance in myelogenous leukemia during chemotherapy.
- || Clinical, Journal: Expression of KLRG1 and CD127 defines distinct CD8 subsets that differentially impact patient outcome in follicular lymphoma. (Pubmed Central) - Jan 11, 2022
These results show a potential novel strategy for intervention chemoresistance in myelogenous leukemia during chemotherapy. Taken together, these results reveal not only a biological and prognostic role for KLRG1/CD127-defined CD8 subsets in FL but also a potential role for PI3K inhibitors to manipulate the differentiation of CD8 T cells, thereby promoting a more effective antitumor immune response.
- | Journal: MiR-508-3p promotes proliferation and inhibits apoptosis of middle ear cholesteatoma cells by targeting PTEN/PI3K/AKT pathway. (Pubmed Central) - Jan 11, 2022
Rescue assays confirmed that PTEN could reverse the effect of miR-508-3p overexpression on cell proliferation. In a word, this study validated that the development of cholesteatoma may regulated by hsa_circ_0000007/miR-508-3p/ PTEN/ PI3K/Akt axis.
- | sevoflurane / Generic mfg., isoflurane / Generic mfg.
Preclinical, Journal: Sevoflurane and isoflurane inhibit KCl-induced, Rho kinase-mediated, and PI3K-participated vasoconstriction in aged diabetic rat aortas. (Pubmed Central) - Jan 11, 2022
SEVO (3 MAC), ISO (1, 2, 3 MAC), LY294002 and Y27632 have more significant inhibitory effect on the contraction of vascular smooth muscle in aged T2MD rats. The mechanism of SEVO and ISO in vascular tension in T2DM is partly due to changes in PI3K and/or Rho kinase activity.
- | LY294002 / Eli Lilly
Journal: Saponins of Momordica charantia increase insulin secretion in INS-1 pancreatic β-cells via the PI3K/Akt/FoxO1 signaling pathway. (Pubmed Central) - Jan 11, 2022
Moreover, saponins increased the phosphorylation of Akt protein and decreased the protein level of FoxO1, which were both reversed by the PI3K inhibitor ly294002...The immunofluorescence results also confirmed this tendency. In conclusion, our findings improve our understanding of the function of saponins in INS-1 pancreatic β-cells and suggest that saponins may increase insulin secretion via the PI3K/Akt/FoxO1 signaling pathway.
- | cisplatin / Generic mfg.
Journal: A PLCB1-PI3K-AKT signaling axis activates EMT to promote cholangiocarcinoma progression. (Pubmed Central) - Jan 11, 2022
PLCB1 expression was regulated by miR-26b-5p through direct interaction with PLCB1 3'UTR. Collectively, these data identify a PLCB1-PI3K-AKT signaling axis vital for CCA development and EMT, suggesting that AKT can be used as a therapeutic target to overcome chemotherapy resistance in CCA patients with high PLCB1 expression.
- | Journal: PIK3CA mutation affects the proliferation of colorectal cancer cells through the PI3K-MEK/PDK1-GPT2 pathway. (Pubmed Central) - Jan 11, 2022
Inhibiting MEK and PDK1 concurrently could effectively inhibit the proliferation of CRC cells. Targeting the MEK and PDK1 signaling pathway may provide a novel strategy for the treatment of PIK3CA‑mutated CRC.
- | AZD-3965 / Cancer Research UK, pictilisib (GDC-0941) / Roche
Biomarker, Journal: Metabolic drug survey highlights cancer cell dependencies and vulnerabilities. (Pubmed Central) - Jan 11, 2022
Mechanistic characterization of selective responses to the PI3K inhibitor pictilisib, the fatty acid synthase inhibitor GSK2194069, and the SLC16A1 inhibitor AZD3965, bring forth biomarkers of drug response. Phenotypic screening using CLIMET represents a valuable tool to probe cellular metabolism and identify metabolic dependencies at large.
- | gemcitabine / Generic mfg.
Journal: Berberine enhances gemcitabine‑induced cytotoxicity in bladder cancer by downregulating Rad51 expression through inactivating the PI3K/Akt pathway. (Pubmed Central) - Jan 11, 2022
BER additively inhibited tumor growth and Ki67 expression when combined with GEM in vivo. These results suggest that BER can enhance GEM‑induced cytotoxicity in BC by downregulating Rad51 expression through inactivating the PI3K/Akt pathway, which may represent a novel therapeutic target for BC treatment.
- | Journal: VEGFB Promotes Myoblasts Proliferation and Differentiation through VEGFR1-PI3K/Akt Signaling Pathway. (Pubmed Central) - Jan 11, 2022
However, the inhibition of PI3K/Akt/mTOR blocked the promotion of C2C12 myoblasts differentiation induced by VEGFB, indicating the involvement of the PI3K/Akt pathway. To conclude, these findings showed that VEGFB promoted C2C12 myoblast proliferation and differentiation via the VEGFR1-PI3K/Akt signaling pathway, providing new insights into the regulation of skeletal muscle development.
- | Journal: Methylation and mutation of the inhibin‑α gene in human melanoma cells and regulation of PTEN expression and AKT/PI3K signaling by a demethylating agent. (Pubmed Central) - Jan 11, 2022
In addition, mutations in the tumor suppressor inhibin‑α, PTEN and p53 genes were not associated with transcriptional silencing, gene expression and cell growth as analyzed through experiments and literature reviews. These data demonstrated that methylation and mutations were associated with the inhibin‑α gene in human melanoma cells and indicated the regulation of PTEN expression and AKT/PI3K signaling by a demethylating agent.
- | Journal: Inhibition of Brain GTP Cyclohydrolase I Attenuates 3-Nitropropionic Acid-Induced Striatal Toxicity: Involvement of Mas Receptor/PI3k/Akt/CREB/ BDNF Axis. (Pubmed Central) - Jan 11, 2022
Interestingly, all the previous effects were blocked by co-administration of WM with DAHP. In conclusion, DAHP exerts neuroprotective effect against neuronal loss induced by 3-NP administration via inhibition of GTPCH I and iNOS activity and activation of MasR/PI3K/Akt/CREB/BDNF/TrKB axis besides its antioxidant and anti-inflammatory effect.
- | LY294002 / Eli Lilly
Journal: CPNE3 regulates the cell proliferation and apoptosis in human Glioblastoma via the activation of PI3K/AKT signaling pathway. (Pubmed Central) - Jan 11, 2022
Our results showed that the expression of CPNE3 promotes cell proliferation by inhibiting cell apoptosis via activating PI3K/AKT pathway. Thereby enhancing the progression of GBM, which suggest that CPNE3 may play as a tumorigenesis gene may become a promising potential therapeutic target for human GBMs.
- | Journal: EPDR1, Which Is Negatively Regulated by miR-429, Suppresses Epithelial Ovarian Cancer Progression via PI3K/AKT Signaling Pathway. (Pubmed Central) - Jan 11, 2022
In conclusion, our study validated that EPDR1, negatively regulated by miR-429, played an important role as a tumor-suppressor gene in EOC development via inhibition of the PI3K/AKT pathway. The miR-429/EPDR1 axis might provide novel therapeutic targets for individualized treatment of EOC patients in the future.
- || Review, Journal: G-protein coupled receptor, PI3K and Rho signaling pathways regulate the cascades of Tau and amyloid-β in Alzheimer's disease. (Pubmed Central) - Jan 11, 2022
Apart from various GPCR signaling pathways, GPCR regulating/ interacting proteins are involved in the pathogenesis of Alzheimer's disease. These include several small GTPases, Ras homolog enriched in brain, GPCR associated sorting proteins, β-arrestins, etc., that play a critical role in disease progression and has been elaborated in this review.
- cyclophosphamide / Generic mfg., sirolimus / Generic mfg.
Evidence of PI3K signalling activation and the potential for chemoprotection in human ovariancortex exposed to cyclophosphamide () - Jan 11, 2022 - Abstract #Fertility2022Fertility_232;
Exposure to 4-HC also compromised the histological health of primordial follicles (23%±5 of primordial follicles were classed as unhealthy versus 7%±3 in controls). These data provide evidence that in vitro exposure to cyclophosphamide upregulates PI3K signalling in human ovarian cortex and compromises the health of primordial follicles, in addition to identifying potential approaches that can be used to ameliorate these chemotherapy-induced effects.
- cisplatin / Generic mfg.
Chemotherapy activates MAPK, PI3K/AKT and TOR signalling in mouse spermatogonial stem celllines () - Jan 11, 2022 - Abstract #Fertility2022Fertility_193;
These results pave the way for exploring strategies for fertility preservation, for example by targeting specific signalling and DNA damage response pathways. This work has been supported by SRF Academic Scholarship 2019 and UKRI MR/S017151/1.
- || Clinical, Journal: Evaluation of B-cell intracellular signaling by monitoring the PI3K-Akt axis in patients with common variable immunodeficiency and activated phosphoinositide 3-kinase delta syndrome. (Pubmed Central) - Jan 8, 2022
Intracellular flow cytometry can be routinely employed to explore alterations in the PI3K-Akt-mTOR pathway in B cells from patients with PADs. AKT and S6 phosphorylation levels are informative biomarkers that could be employed as mTOR inhibitors for monitoring therapies targeting this pathway.
- | Journal: The depletion of Circ-PRKDC enhances autophagy and apoptosis in T-cell acute lymphoblastic leukemia via microRNA-653-5p/Reelin mediation of the PI3K/AKT/mTOR signaling pathway. (Pubmed Central) - Jan 8, 2022
The knockdown of miR-653-5p abrogated the silencing of Circ-PRKDC-induced effects in T-ALL cells. The depletion of Circ-PRKDC elevated miR-653-5p to silence RELN-mediated PI3K/AKT/mTOR signaling activation, thereby enhancing autophagy and apoptosis in T-ALL cells.
- | Journal: Modulation of the PI3K/Akt/mTOR signaling pathway by probiotics as a fruitful target for orchestrating the immune response. (Pubmed Central) - Jan 8, 2022
However, longitudinal human studies are possibly required to verify more conclusively whether the investigational tools used to understand the regulation of these pathways might provide effective approaches in the prevention and treatment of various disorders. In this Review, we summarize the experimental evidence from recent peer-reviewed studies and provide a brief overview of the causal relationship between the effects of probiotics and their metabolites on the components of PI3K/Akt/mTOR signaling pathways and human disease.
- | Nexavar (sorafenib) / Bayer, Amgen
Journal: Enhanced anticancer activity by the combination of vinpocetine and sorafenib via PI3K/AKT/GSK-3β signaling axis in hepatocellular carcinoma cells. (Pubmed Central) - Jan 8, 2022
Our study revealed that vinpocetine plus sorafenib could suppress the cytoprotective autophagy induced by vinpocetine and subsequently show synergistically anti-HCC activity via activating GSK-3β and the combination of vinpocetine and sorafenib might reverse sorafenib resistance via the PI3K/protein kinase B/GSK-3β signaling axis. Thus, vinpocetine may be a potential candidate for sorafenib sensitization and HCC treatment, and our results may help to elucidate more effective therapeutic options for HCC patients with sorafenib resistance.
- | Journal: miR-125a-5p impairs the metastatic potential in breast cancer via IPK1 targeting. (Pubmed Central) - Jan 8, 2022
Overall, these results identify a novel axis primed by miR-125a-5p to downregulate IPK1 gene that inhibits metastasis. Thus, administration of myo-Inositol can activate this axis as a molecular target therapy in breast cancer.
- | MK-2206 / Merck (MSD)
Journal, IO biomarker: Aloe-emodin prevents nerve injury and neuroinflammation caused by ischemic stroke via the PI3K/AKT/mTOR and NF-κB pathway. (Pubmed Central) - Jan 8, 2022
Overall, our study suggests that AE protected against cerebral ischemia-reperfusion injury probably via the PI3K/AKT/mTOR and NF-κB signaling pathways. Thus, these results indicated that AE could be a promising first-line therapy for preventing and treating ischemic stroke and can be used as functional food.
- | Journal, IO biomarker: Bcl2-associated athanogene 4 promotes the invasion and metastasis of gastric cancer cells by activating the PI3K/AKT/NF-κB/ZEB1 axis. (Pubmed Central) - Jan 8, 2022
Luciferase reporter and chromatin immunoprecipitation assays verified that p65 binds to the promoter of ZEB1 to upregulate its transcription. Our results demonstrate that BAG4 plays an oncogenic role in the invasion and metastasis of GC cells by activating the PI3K/AKT/NF-κB/ZEB1 axis to induce epithelial-mesenchymal transition.
- | doxycycline / Generic mfg.
Journal: Effect of the Notch1-mediated PI3K-Akt-mTOR pathway in human osteosarcoma. (Pubmed Central) - Jan 8, 2022
In summary, our results revealed that Notch1 activation by doxycycline induces S phase arrest, apoptosis and autophagy by blocking PI3K/Akt/mTOR signalling in human osteosarcoma cells. Notch1 may be a potential clinical antitumour target for osteosarcoma therapy.
- | Journal: Secretory autophagy-induced bladder tumour-derived extracellular vesicle secretion promotes angiogenesis by activating the TPX2-mediated phosphorylation of the AURKA-PI3K-AKT axis. (Pubmed Central) - Jan 8, 2022
The increased exogenous active CTSB in endothelial cells by directly ingesting EV-CTSB prominently activated the TPX2-mediated phosphorylation of the AURKA-PI3K-AKT axis, increased VEGFA expression, and promoted angiogenesis. Our findings not only verify that EV-CTSB can be a promising target for antiangiogenic strategies in bladder cancer, but also reveal a novel action pattern based on secretory autophagy-induced EV secretion which is enlightening to explore crosstalk in the TME from various perspectives.
- | Tazverik (tazemetostat) / Epizyme, Eisai, Aliqopa (copanlisib) / Bayer
Journal: EZH2 inhibition confers PIK3CA-driven lung tumors enhanced sensitivity to PI3K inhibition. (Pubmed Central) - Jan 8, 2022
This study suggests a promising combination therapy to combat lung cancers with PIK3CA mutation or amplification. Both copanlisib, the PI3K inhibitor, and tazemetostat, the EZH2 inhibitor, are FDA-approved, which should enhance the clinical translation of this work.
- | Journal: Repressing MYC by targeting BET synergizes with selective inhibition of PI3Kα against B cell lymphoma. (Pubmed Central) - Jan 8, 2022
An unbiased screening with drugs approved or in clinical trials for the therapy of BCL identified that the clinical BET (Bromodomain and Extra Terminal domain) inhibitor OTX015 significantly potentiated the activity of CYH33 against BCL in vitro and in vivo, which was associated with enhanced inhibition on c-MYC expression and induction of cell cycle arrest and apoptosis. Our findings provide the rationale of combined CYH33 with BET inhibitors for the therapy of B cell lymphoma.
- | Journal: Propofol Inhibits Thyroid Cancer Cell Proliferation, Migration, and Invasion by Suppressing SHH and PI3K/AKT Signaling Pathways via the miR-141-3p/BRD4 Axis. (Pubmed Central) - Jan 8, 2022
Both miR-141-3p and BRD4 can regulate the activity of SHH and PI3K/AKT signaling pathways. Propofol can inhibit the activity of SHH and PI3K/AKT pathways by targeting downregulating BRD4 through miR-141-3p, thereby inhibiting the phenotype of TPC-1 cells.
- | Journal: Soluble αKlotho downregulates Orai1-mediated store-operated Ca entry via PI3K-dependent signaling. (Pubmed Central) - Jan 7, 2022
Functionally, we further show that soluble αKlotho ameliorates serum-stimulated SOCE and cell migration in breast and lung cancer cells. These results demonstrate that soluble αKlotho downregulates SOCE by inhibiting PI3K-driven vesicular exocytosis of the Orai1 channel and contributes to the suppression of SOCE-mediated tumor cell migration.
- || LY294002 / Eli Lilly
Review, Journal: Pathophysiology and Therapeutic Relevance of PI3K(p110α) Protein in Atrial Fibrillation - A Non-interventional Molecular Therapy Strategy. (Pubmed Central) - Jan 7, 2022
We also considered PI3K(p110α) in AF gene association, with the aim of identifying mechanistic links between the ever increasingly well-defined genetic loci (regions and genes) and AF. Such mechanisms will aid in identifying new drug targets for arrhythmogenic substrate and AF.
- | Journal: Berberine ameliorates neuronal AD-like change via activating Pi3k/PGCε pathway. (Pubmed Central) - Jan 7, 2022
Additionally, it suppressed the generation of Aβ42 and ameliorated neuron axon damage. Finally, berberine improves DM (diabetes mellitus)-induced cognitive impairment.
- | Journal: The miR-302s/367 Cluster Inhibits the Proliferation and Apoptosis in Sheep Fetal Fibroblasts via the Cell Cycle and PI3K-Akt Pathways. (Pubmed Central) - Jan 7, 2022
The results showed that miR-302s/367 could not reprogram SFFs into iPSCs; however, they could inhibit both the proliferation and apoptosis of SFFs by targeting CDK2, E2F1, E2F2, and PTEN in the cell cycle and PI3K-Akt pathways. Based on our findings, a novel mechanism was proposed in which the miR-302s/367 family functions in both the proliferation and apoptosis of somatic cells in mammals, suggesting that caution is needed when using miR-302s/367 as therapeutic agent.
- | sirolimus / Generic mfg.
Preclinical, Journal: The p70S6K/PI3K/MAPK feedback loop releases the inhibition effect of high-dose rapamycin on rat mesangial cell proliferation. (Pubmed Central) - Jan 7, 2022
Moreover, our results revealed that 1000 nmol/L rapamycin led to Raf1-MEK1/2-ERK pathway activation through a p70S6K-PI3K-mediated feedback loop in MCs. This study demonstrated that high-dose rapamycin leads to ERK1/2 activation through a p70S6K/PI3K/MAPK feedback loop in rat MCs, thus reducing the inhibitory effect of rapamycin on MC proliferation.
- | GSK690693 / GSK, LY294002 / Eli Lilly
Journal: Melatonin-mediated MT2 attenuates colitis induced by dextran sodium sulfate via PI3K/AKT/Nrf2/SIRT1/RORα/NF-κB signaling pathways. (Pubmed Central) - Jan 7, 2022
This study demonstrated that high-dose rapamycin leads to ERK1/2 activation through a p70S6K/PI3K/MAPK feedback loop in rat MCs, thus reducing the inhibitory effect of rapamycin on MC proliferation. Melatonin-mediated MT2 activated PI3K/AKT/Nrf2/RORα/SIRT1 pathway and suppressed NF-κB pathway, ultimately improved DSS-induced colitis, which provides evidence for melatonin as an efficient therapy against oxidative stress associated IBD.
- | Preclinical, Journal: Erianin, the main active ingredient of Dendrobium chrysotoxum Lindl, inhibits precancerous lesions of gastric cancer (PLGC) through suppression of the HRAS-PI3K-AKT signaling pathway as revealed by network pharmacology and in vitro experimental verification. (Pubmed Central) - Jan 7, 2022
Our results suggest that Erianin may be a promising candidate in the development of prevention and treatment methods for PLGC. This study provided experimental evidence for the clinical use of Dendrobium chrysotoxum Lindl to treat PLGC and prevent gastric cancer.
- || Retrospective data, Review, Journal, Monotherapy: The effectiveness of monotherapy with PI3K/AKT/mTOR pathway inhibitors in ovarian cancer: A meta-analysis. (Pubmed Central) - Jan 7, 2022
Given the toxicity profile, we suggest that current treatment with PI3K/AKT/mTOR inhibitors should not be initiated unless in clinical trials. Furthermore, improved biomarkers to measure functional PI3K/AKT/mTOR pathway activity are needed to optimize patient selection.
- | Journal: Kaempferol-induced GPER upregulation attenuates atherosclerosis via the PI3K/AKT/Nrf2 pathway. (Pubmed Central) - Jan 7, 2022
However, the protective effects of kaempferol were blocked through co-treatment with si-GPER. The beneficial effects of kaempferol against postmenopausal AS are associated with the PI3K/AKT/Nrf2 pathways, mediated by the activation of GPER.
- | ZSTK474 / Zenyaku Kogyo
Journal, PD(L)-1 Biomarker, IO biomarker: Cancer immunotherapy with PI3K and PD-1 dual-blockade via optimal modulation of T cell activation signal. (Pubmed Central) - Jan 7, 2022
The beneficial effects of kaempferol against postmenopausal AS are associated with the PI3K/AKT/Nrf2 pathways, mediated by the activation of GPER. PI3K inhibitor in the combination with ICB with the optimized protocol fine-tuned T cell activation signaling for antitumor immunity via decreasing Tregs and optimizing memory CD8 T cell responses, illustrating a promising combination therapy.
- | Journal, PD(L)-1 Biomarker, IO biomarker: A Dual PI3K/HDAC Inhibitor Induces Immunogenic Ferroptosis to Potentiate Cancer Immune Checkpoint Therapy. (Pubmed Central) - Jan 7, 2022
Mechanistically, BEBT-908-induced ferroptosis led to upregulation of major histocompatibility complex class I (MHC I) and activation of endogenous interferon gamma (IFNγ) signaling in cancer cells via the STAT1 signaling pathway. The dual PI3K/HDAC inhibitor BEBT-908 is a promising targeted therapeutic agent against multiple cancer types that promotes immunogenic ferroptosis and enhances the efficacy of immunotherapy.